By Nick Paul Taylor
President Donald Trump is considering fast-tracking the authorization of AstraZeneca’s COVID-19 vaccine to ensure a jab is available in time for the November election, according to the Financial Times. The mooted plan is to allow AstraZeneca to gain emergency use authorization on the basis of a 10,000-subject U.K. clinical trial.
read more
By Heather Landi
As drug giant Johnson & Johnson gears up for the industry's largest COVID-19 vaccine trial to date, Fierce Healthcare spoke with one of the company's top scientists about the hunt for a vaccine. Find out how Hanneke Schuitemaker's team has been able to work at an accelerated pace and the one thing she wants the public to know.
read more
By Angus Liu
In the landmark ACTT-1 clinical trial run by the National Institutes of Health, the benefit of Gilead Sciences’ remdesivir wasn't obvious in moderate COVID-19 cases. In a new clinical trial, the antiviral once again showed mixed results in moderately ill patients, raising questions as to whether it’s up for a full FDA nod covering that population.
read more
By Kyle Blankenship
Moderna faces a slew of challenges in keeping with its bigger competitors in the chase for a COVID-19 vaccine, most crucially its limited manufacturing and distribution capacity. With its supply chain on the upswing, Moderna is looking to nab an expansive distribution deal with the EU as a complement to its multibillion-dollar U.S. pact.
read more
By Tina Reed
A majority of long-term care providers indicated they won't last another year under current financial conditions caused by the COVID-19 pandemic, recent surveys found.
read more
By Paige Minemyer
Insurers posted "unusually strong" financial performance in the second quarter, according to a new analysis from Moody's Investors Service.
read more
By Robert King
A hospital industry report pegs losses for Florida hospitals from COVID-19 at nearly $4 billion through the end of June, as federal relief funds failed to fill the gap.
read more
By Kyle Blankenship
In the hunt for a novel coronavirus vaccine, British drugmaker AstraZeneca has raced to the front of the pack with promising interim data and a slew of proposed supply deals. One of its earliest partners in the effort, New Jersey CDMO Catalent, is now adding to its responsibilities as the vaccine nears regulatory scrutiny.
read more
By Eric Sagonowsky
It’s been a contentious week at the FDA after attacks from President Donald Trump and his allies, who've claimed “deep state” employees within the agency are undercutting the fight against the COVID-19 pandemic. The accusation met with quick pushback from former agency officials and lawmakers alike.
read more
By Ben Adams
Singapore-based Aslan Pharmaceuticals is hitting go again on its stalled dermatitis study.
read more
